Analysts Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) PT at $57.60

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) has received a consensus rating of "Moderate Buy" from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $58.83.

A number of research firms have recently weighed in on ESTA. BTIG Research boosted their target price on Establishment Labs from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Monday. JPMorgan Chase & Co. cut their target price on shares of Establishment Labs from $61.00 to $50.00 and set an "overweight" rating on the stock in a report on Wednesday, August 7th. Stephens reiterated an "overweight" rating and set a $68.00 price target on shares of Establishment Labs in a report on Wednesday, August 7th. Finally, Citigroup raised their price target on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a "neutral" rating in a report on Tuesday, October 1st.

Establishment Labs Price Performance

Shares of ESTA traded up $1.45 during midday trading on Monday, reaching $41.28. The stock had a trading volume of 314,767 shares, compared to its average volume of 378,879. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -13.31 and a beta of 1.20. The company's 50-day moving average is $42.46 and its 200 day moving average is $46.82. Establishment Labs has a 12-month low of $16.96 and a 12-month high of $60.12.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The business had revenue of $44.12 million for the quarter, compared to the consensus estimate of $43.10 million. During the same quarter in the previous year, the business earned ($0.65) earnings per share. The firm's revenue was down 9.2% on a year-over-year basis. On average, equities analysts predict that Establishment Labs will post -2.27 EPS for the current fiscal year.

Institutional Trading of Establishment Labs

Several large investors have recently bought and sold shares of the company. Capital Research Global Investors purchased a new stake in shares of Establishment Labs in the 1st quarter worth about $45,888,000. William Blair Investment Management LLC purchased a new stake in Establishment Labs in the first quarter worth about $21,415,000. First Turn Management LLC purchased a new position in shares of Establishment Labs during the second quarter valued at approximately $16,812,000. Sofinnova Investments Inc. boosted its holdings in Establishment Labs by 204.1% in the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company's stock worth $19,505,000 after acquiring an additional 288,082 shares in the last quarter. Finally, Divisadero Street Capital Management LP purchased a new stake in Establishment Labs during the 2nd quarter valued at about $5,829,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.